140 related articles for article (PubMed ID: 38170793)
1. Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy.
Lu Q; Zhou W; Fan L; Ding T; Wang W; Zhang X
Anticancer Drugs; 2024 Mar; 35(3):305-314. PubMed ID: 38170793
[TBL] [Abstract][Full Text] [Related]
2. Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy.
Sng CCT; Kallor AA; Simpson BS; Bedran G; Alfaro J; Litchfield K
Front Immunol; 2024; 15():1347542. PubMed ID: 38558815
[TBL] [Abstract][Full Text] [Related]
3. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
4. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
5. Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.
Zhou C; Wei Z; Zhang L; Yang Z; Liu Q
Front Oncol; 2020; 10():593989. PubMed ID: 33363023
[TBL] [Abstract][Full Text] [Related]
6. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
[TBL] [Abstract][Full Text] [Related]
7. PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions.
Tan X; Xu L; Jian X; Ouyang J; Hu B; Yang X; Wang T; Xie L
Cells; 2023 Mar; 12(5):. PubMed ID: 36899918
[TBL] [Abstract][Full Text] [Related]
8. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract][Full Text] [Related]
9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
10. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
11. [Identification of neoantigens and development of antigen-specific immunotherapy].
Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
[TBL] [Abstract][Full Text] [Related]
12. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
13. A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
Lazdun Y; Si H; Creasy T; Ranade K; Higgs BW; Streicher K; Durham NM
Mol Cancer Res; 2021 Mar; 19(3):498-506. PubMed ID: 33257508
[TBL] [Abstract][Full Text] [Related]
14. Identification of neoantigens derived from alternative splicing and RNA modification.
Park J; Chung YJ
Genomics Inform; 2019 Sep; 17(3):e23. PubMed ID: 31610619
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.
Shi Y; Jing B; Xi R
Genome Biol; 2023 Jul; 24(1):169. PubMed ID: 37461029
[TBL] [Abstract][Full Text] [Related]
16. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
Okada M; Shimizu K; Fujii SI
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
[TBL] [Abstract][Full Text] [Related]
17. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
18. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
19. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
[TBL] [Abstract][Full Text] [Related]
20. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
